Optimizing radiotherapy schedules for elderly glioblastoma multiforme patients

Expert Review of Anticancer Therapy

Volumn 8, Issue 5, 2008, Pages 733-741

  Clarke, James W ^a   Chang, Eric L ^b   Levin, Victor A ^b   Mayr, Nina A ^a   Hong, Eugene ^c   Cavaliere, Robert ^d   Lo, Simon S ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Elderly; Glioblastoma; Hypofractionation; Radiotherapy; Short course; Survival

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

AGE; AGED; BRAIN TUMOR; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; FUNCTIONAL STATUS; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MORBIDITY; POSTOPERATIVE CARE; PROGNOSIS; RADIATION DOSE; REVIEW; RISK ASSESSMENT; SURVIVAL TIME; TREATMENT DURATION; ADJUVANT THERAPY; COMPUTER ASSISTED RADIOTHERAPY; MULTIMODALITY CANCER THERAPY; RADIATION DOSE FRACTIONATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; GLIOBLASTOMA; HUMANS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL;

EID: 45849115470     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.5.733     Document Type: Review

References (48)

1. Greig NH, Ries LG, Yancik R, Rapoport SI. Increasing annual incidence of primary malignant brain tumors in the elderly. J. Natl. Cancer Inst. 82(20), 1621-1624 (1990).
2. Werner MH, Phuphanich S, Lyman GH. The increasing incidence of malignant gliom as and primary central nervous system lymphoma in the elderly. Cancer 76(9), 1634-1642 (1995).
3. Walker MD, Alexander E Jr, Hunt WE et al. Evaluation of BCNU and/ or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg. 49(3), 333-343 (1978).
4. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in tile radiotherapy of malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 5(10), 1725-1731 (1979).
5. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br. J. Cancer 64(4), 769-774 (1991).
6. Curran WJ Jr, Scott CB, Nelson JS et al. A randomized trial of accelerated hyperfractionated radiation therapy and bis-chloroethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83-02. Cancer 70(12), 2909-2917 (1992).
7. Deutsch M, Green SB, Strike TA et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int. J. Radiat. Oncol. Biol. Phys. 16(6), 1389-1396 (1989).
8. Kristiansen K, Hagen S, Kollevold T et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 47(4), 649-652 (1981).
9. Nelson DF, Diener-West M, Weinstein AS et al. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. Int. J. Radiat. Oncol. Biol. Phys. 12(10), 1793-1800 (1986).
10. Nelson DF, Curran WJ Jr, Scott C et al. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma - possible advantage observed at 72.0 Gy in 1.2 Gy BID fractions: report of the Radiation Therapy Oncology Group Protocol 8302. Int. J. Radiat. Oncol. Biol. Phys. 25(2), 193-207 (1993).
11. Payne DG, Simpson WJ, Keen C, Platts ME. Malignant astrocytoma: hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial. Cancer 50(11), 2301-2306 (1982).
12. Phillips TL, Levin VA, Ahn DK et al. Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study. Int. J. Radiat. Oncol. Biol. Phys. 21(3), 709-714 (1991).
13. Levin VA, Prados MR, Wara WM et al. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lormistine, and vincristine for the treatment of anaplastic gliomas. Int. J. Radiat. Oncol. Biol. Phys. 32(1), 75-83 (1995).
14. Levin VA, Uhm, JH, Jaeckle KA et al. Phase III randomized study of postradiotherapy chemotherapy with α-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin. Cancer Res. 6(10), 3878-3884 (2000).
15. Prados MD, Larson DA, Lamborn K et al. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. Int. J. Radiat. Oncol. Biol. Phys. 40(1), 57-63 (1998).
16. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005).
17. Athanassiou H, Synodinou M, Maragoudakis E et al. Randomized Phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 23(10), 2372-2377 (2005).
18. Curran WJ Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J. Natl. Cancer Inst. 85(9), 704-710 (1993).
19. Scott CB, Scarantino C, Urtasun R et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant ghoma patients: a report using RTOG 90-06. Int. J. Radiat. Oncol. Biol. Phys. 40(1), 51-55 (1998).
20. Mohan DS, Sub JH, Phan JL et al. Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Int. J. Radiat. Oncol. Biol. Phys. 42(5), 981-987 (1998).
21. Whittle IR, Denholm SW, Gregor A. Management of patients aged over 60 years with supratentorial glioma: lessons from an audit. Surg. Neurol. 36(2), 106-111 (1991).
22. Paszat L, Laperriere N, Groome P et al. A population-based study of glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 51(1), 100-107 (2001).
23. Shaw EG. Nothing ventured, nothing gained: treatment of glioblastoma multiforme in the elderly. J. Clin. Oncol. 22(9), 1540-1541 (2004).
24. Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir. (Wien) 145(1), 5-10 (2003).
25. Brandes AA, Vastola F, Basso U et al. A prospective study on glioblastoma in the elderly. Cancer 97(3), 657-662 (2003).
26. Pelloski CE, Mahajan A, Maor M et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin. Cancer Res. 11(9), 3326-3334 (2005).
27. Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N. Engl. J. Med. 356(15), 1527-1535 (2007).
28. Halperin EC. Malignant gliomas in older adults with poor prognostic signs. Getting nowhere, and taking a long time to do it. Oncology (Williston Park) 9(3), 229-234 (1995).
29. Hall EJ. Radiobiology for the Radiologist. Lippincott & Wilkins, PA, USA (2006).
30. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br. J. Radiol. 62(740), 679-694 (1989).
31. Haas-Kogan DA, Yount G, Haas M et al. p53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 36(1), 95-103 (1996).
32. Haas-Kogan DA, Kogan SS, Yount G et al. p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. Int. J. Radiat. Oncol. Biol. Phys. 43(2), 399-403 (1999).
33. Qi XS, Schultz CJ, Li XA. An estimation of radiobiologic parameters from clinical outcomes for radiation treatment planning of brain tumor. Int. J. Radiat. Oncol. Biol. Phys. 64(5), 1570-1580 (2006).
34. Chang EL, Yi W, Allen PK et al. Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 56(2), 519-528 (2003).
35. Bauman GS, Gaspar LE, Fisher BJ et al. A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 29(4), 835-839 (1994).
36. Ford JM, Stenning SP, Boote DJ et al. A short fractionation radiotherapy treatment for poor prognosis patients with high grade glioma. Clin. Oncol. (R. Coll. Radiol.) 9(1), 20-24 (1997).
37. Hulshof MC, Schimmel EC, Andries Bosch D, Gonzalez Gonzalez D. Hypofractionation in glioblastoma multiforme. Radiother. Oncol. 54(2), 143-148 (2000).
38. Kleinberg L, Slick T, Enger C et al. Short course radiotherapy is an appropriate option for most malignant glioma patients. Int. J. Radiat. Oncol. Biol. Phys. 38(1), 31-36 (1997).
39. Slotman BJ, Kralendonk JH, van Alphen HA, Kamphorst W, Karim AB. Hypofractionated radiation therapy in patients with glioblastoma multiforme: results of treatment and impact of prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 34(4), 895-898 (1996).
40. Tamura M, Nakamura M, Kunimine H et al. Large dose fraction radiotherapy in the treatment of glioblastoma. J. Neurooncol. 7(2), 113-119 (1989).
41. Thomas R, James N, Guerrero D et al. Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. Radiother. Oncol. 33(2), 113-116 (1994).
42. McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched pair survival analysis with MRC controls. Radiother. Oncol. 67(2), 177-182 (2003).
43. Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J. Clin. Oncol. 22(9), 1583-1588 (2004).
44. Lutterbach J, Ostertag C. What is the appropriate radiotherapy protocol for older patients with newly diagnosed glioblastoma? J. Clin. Oncol. 23(12), 2869-2870 (2005).
45. Phillips C, Guiney M, Smith J et al. A randomized trial comparing 35Gy in ten fractions with 60Gy in 30 fractions of cerebral irradiation for glioblastoma multiforme and older patients with anaplastic astrocytoma. Radiother. Oncol. 68(1), 23-26 (2003).
46. Mirimanoff RO, Gorlia T, Mason W et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 Phase III randomized trial. J. Clin. Oncol. 24(16), 2563-2569 (2006).
47. Chinot OL, Barrie M, Frauger E et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 100(10), 2208-2214 (2004).
48. Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97(9), 2262-2266 (2003).